ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Imaging Advances in the Management of Kidney Cancer.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Reasoning in machine vision by learning fast and slow thinking.Nature communications · 2026Article
- Machine learning based classification of aggressive and malignant renal tumors from multimodal data.PLOS digital health · 2026Article
- Examining the evolving landscape of kidney cancer mortality in the United States.The oncologist · 2025Article
- Kidney Cancer Incidence among Non-Hispanic American Indian and Alaska Native Populations in the United States, 1999 to 2020.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Cancer Incidence Trends in Successive Social Generations in the US.JAMA network open · 2024Article
- Patient-specific, deliverable, and self-expandable surgical guide development and evaluation using 4D printing for laparoscopic partial nephrectomy.Scientific reports · 2024Article
- Polarization-sensitive optical coherence tomography for renal tumor detection inOptics and lasers in engineering · 2024Article
- Artificial Intelligence in Renal Cell Carcinoma Histopathology: Current Applications and Future Perspectives.Diagnostics (Basel, Switzerland) · 2023Review
- Spectrum of Presentations and Management Strategies in Renal Angiomyolipoma.Journal of kidney cancer and VHL · 2022Article
- Predictive value of contrast-enhanced ultrasound combined with conventional ultrasound in solid renal parenchymal lesions.The British journal of radiology · 2021Article
- Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment.Radiology · 2019Review
- Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Disparities in Trend of Renal Cell Carcinoma Mortality in the United States.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer. A host of imaging response criteria have been developed to characterize the response to targeted and immune therapies and correlate with patient outcomes, each with strengths and limitations. Recent efforts to advance the field are aimed at increasing objectivity with quantitative techniques and the use of banks of imaging data to match the vast genomic data that are becoming available. The emerging field of radiogenomics has the potential to transform further the role of imaging in kidney cancer management through eventual noninvasive characterization of the tumor histology and genetic microenvironment in single renal masses and/or metastatic disease. We review of the effect of currently available imaging techniques in the management of patients with kidney cancer, including localized, locally advanced, and metastatic disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.